Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BGIICC 2018 /
Neoadjuvant and adjuvant therapy in triple negative breast cancer

18th - 19th Jan 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.01.18
Views: 1429

Prof Banu Arun - MD Anderson Center, Houston, USA

Prof Arun speaks with ecancer at the 10th BGICC in Cairo about treatment prospects for women with triple negative breast cancer.

She outlines that, while chemotherapy can prove effective, adding new-generation adjuvant and neo-adjuvant agents may improve partial clinical response and disease survival.

Prof Arun highlights data from recent trials ASCO 2017 on velaparib with neo-adjuvant chemotherapy, which show a greater benefit with platinum therapies at a cost of greater toxicity.

Prof Arun also spoke with ecancer about treatment strategies for BRCA tumours, here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation